Dermatology · Small Molecule
The ongoing trial of Deucravacitinib for Pityriasis Rubra Pilaris represents a potential breakthrough in a niche dermatological area with few existing therapies. Success in this trial could significantly influence competitive positioning and development strategies in dermatology.
Multi-agent research across ingested FDA, EMA, MHRA, PMDA, PubMed, ClinicalTrials.gov, company documents, and Humanexa signals.
Last run 6/22/2026, 6:31:05 AM
Assessment confidence: 67% · The main uncertainty is timing and magnitude of competitive and regulatory follow-through.
The ongoing trial of Deucravacitinib for Pityriasis Rubra Pilaris represents a potential breakthrough in a niche dermatological area with few existing therapies. Success in this trial could significantly influence competitive positioning and development strategies in dermatology. Regulatory context from MHRA (Update on the PATHWAYS clinical trial) supports the near-term read. Assessment grounded in 16 ranked evidence items (8 high-relevance).
Portfolio teams should monitor trial outcomes as they may influence future development strategies in dermatology. The strongest clinical anchor is Deucravacitinib (BMS-986165) for Pityriasis Rubra Pilaris (ClinicalTrials.gov), entity match (deucravacitinib). In Dermatology · Small Molecule, 3 regulatory and 3 competitive items passed relevance filtering for Deucravacitinib.
The most relevant competitive pressure comes from Roche's ENSPRYNG shows 68% relapse reduction in Phase III MOGAD study (Humanexa Signals) — sponsor/company relevance (roche). Secondary pressure from Merck and Gilead Provide Update on Phase 3 KEYNOTE-D46/EVOKE-03 Study. If successful, Deucravacitinib could position itself as a novel treatment option in a niche dermatological market with limited therapies.
Regulatory risk is concentrated around Update on the PATHWAYS clinical trial (MHRA). Moderate corpus alignment. Relevant agencies in corpus: MHRA, FDA. The outcomes of this trial will be critical for regulatory approval processes, impacting labeling and compliance for the drug in this indication.
Update on the PATHWAYS clinical trial
MHRAhigh relevance
Moderate corpus alignment
FDA document
View sourceClinicalTrials.gov: Essentials for Academic Medical Centers - 07/14/2026
FDAhigh relevance
Moderate corpus alignment
FDA document
View sourceClinical trials for medicines: modifying a clinical trial approval
MHRAhigh relevance
Moderate corpus alignment
FDA document
View sourceDeucravacitinib (BMS-986165) for Pityriasis Rubra Pilaris
ClinicalTrials.govhigh relevance
Entity match (deucravacitinib)
FDA document
View sourceA Study of BL-B01D1 in Combination With Osimertinib as Perioperative Therapy in Patients With EGFR-mutated Resectable Non-small Cell Lung Cancer(PANKU-Lung09)
ClinicalTrials.govhigh relevance
Mechanism alignment (IO )
FDA document
View sourceA Multicenter Observational Study to Understand the Clinical Characteristics, Treatment Patterns and Access to Novel Therapies of Patients With Diffuse Large B-Cell Lymphoma in the MEA Region
ClinicalTrials.govhigh relevance
Sponsor/company relevance (AstraZeneca)
FDA document
View sourcePost-Market Clinical Follow-Up (PMCF) Study Evaluating the Safety and Efficacy of Tıpmed™ Revision Hip Prosthesis System
ClinicalTrials.govmedium relevance
Moderate corpus alignment
FDA document
View sourceTesting Early Treatment for Patients With High-Risk Chronic Lymphocytic Leukemia (CLL) or Small Lymphocytic Leukemia (SLL), EVOLVE CLL/SLL Study
ClinicalTrials.govmedium relevance
Moderate corpus alignment
FDA document
View sourceRoche's ENSPRYNG shows 68% relapse reduction in Phase III MOGAD study
Humanexa Signalshigh relevance
Sponsor/company relevance (Roche)
Merck and Gilead Provide Update on Phase 3 KEYNOTE-D46/EVOKE-03 Study
Merckhigh relevance
Sponsor/company relevance (Merck)
FDA document
View sourceRavulizumab Shows Promise in Reducing Delayed Graft Function in Kidney Transplant Patients
Humanexa Signalsmedium relevance
Moderate corpus alignment
In vitro screening of compounds for targeting gastric cancer with Y220C p53 mutation: a molecule combining zinc chelation and Michael acceptor drives CDKN1 and BBC3 expression to restore a p53-depende
PubMedmedium relevance
Moderate corpus alignment
FDA document
View sourceClinical manifestations and ultrasonographic features of lobular endocervical glandular hyperplasia: a retrospective study of 135 patients.
PubMedmedium relevance
Moderate corpus alignment
FDA document
View sourceDevelopment and Preliminary Clinical Evaluation of Multifunctional Operative Support Arm in Reproductive Laparoscopic Surgery: A Randomized Controlled Study.
PubMedmedium relevance
Moderate corpus alignment
FDA document
View sourceAn orthotopic organoid-based model to study early CD8⁺ T cell dysfunction and immunotherapy response in colorectal cancer.
PubMedmedium relevance
Moderate corpus alignment
FDA document
View sourcePrecedents · guidance
Loading regulatory precedents…
View full regulatory analysisCompetitors · threats
Loading competitive findings…
View full competitive analysisThe ongoing trial of Deucravacitinib for Pityriasis Rubra Pilaris represents a potential breakthrough in a niche dermatological area with few existing therapies. Success in this trial could significantly influence competitive positioning and development strategies in dermatology.
If Deucravacitinib proves effective, it could capture market share in a limited therapy landscape, potentially leading to substantial revenue opportunities.
The outcomes of this trial will be critical for regulatory approval processes, impacting labeling and compliance for the drug in this indication.
Key milestones include the completion of the 24-week assessment and biomarker identification results.
Track for follow-up milestones; no immediate action required.